SCHEMBL44904

SCHEMBL44904

NC(Cc1ccc(Cl)cc1Cl)C(=O)O

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC8 Q9BY41 14/20 0.58
HDAC3 O15379 1/20 0.58
HDAC1 Q13547 1/20 0.58
HDAC2 Q92769 1/20 0.58
HDAC6 Q9UBN7 1/20 0.58
CYP2C9 P11712 3/20 0.54
MEN1 O00255 2/20 0.54
ALDH1A1 P00352 2/20 0.54
CYP1A2 P05177 2/20 0.54
HPGD P15428 2/20 0.54
ALOX15 P16050 2/20 0.54
KMT2A Q03164 2/20 0.54
HSD17B10 Q99714 2/20 0.54
TSHR P16473 1/20 0.54
MAPK1 P28482 1/20 0.54
CYP2C19 P33261 1/20 0.54
CYP3A4 P08684 2/20 0.50
USP2 O75604 2/20 0.50
RGS12 O14924 1/20 0.50
PKM P14618 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29350881 1.00 HDAC8 (0.58) HDAC8HDAC3HDAC1HDAC2HDAC6
SCHEMBL44905 1.00 HDAC8 (0.58) HDAC8HDAC3HDAC1HDAC2HDAC6
SCHEMBL1613174 1.00 HDAC8 (0.58) HDAC8HDAC3HDAC1HDAC2HDAC6
SCHEMBL5965416 0.89 HDAC8 (0.52) HDAC8HDAC3HDAC1HDAC2HDAC6
SCHEMBL21690291 0.86 CYP2C9 (0.51) HDAC8HDAC3HDAC1HDAC2HDAC6
SCHEMBL29398382 0.86 CYP2C9 (0.51) HDAC8HDAC3HDAC1HDAC2HDAC6
SCHEMBL29398451 0.86 CYP2C9 (0.51) HDAC8HDAC3HDAC1HDAC2HDAC6
SCHEMBL12958085 0.86 HDAC8 (0.58) HDAC8HDAC3HDAC1HDAC2HDAC6
SCHEMBL29868418 0.86 HDAC8 (0.58) HDAC8HDAC3HDAC1HDAC2HDAC6
SCHEMBL15745971 0.85 HDAC8 (0.57) HDAC8HDAC3HDAC1HDAC2HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1295 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023042201-A1 ANTIMICROBIAL PEPTIDES YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2023-03-23 WO claimed
CN-105143245-B Anti-scaling material 耶路撒冷希伯来大学伊森姆研究发展有限公司 2021-02-05 CN claimed
EP-2951195-B1 ANTIFOULING MATERIALS YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD (IL) 2020-02-19 EP claimed
US-9631100-B2 Antifouling materials YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2017-04-25 US claimed
US-20150368480-A1 ANTIFOULING MATERIALS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) 2015-12-24 US claimed
EP-2951195-A1 ANTIFOULING MATERIALS Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. (IL) 2015-12-09 EP claimed
WO-2014118779-A1 ANTIFOULING MATERIALS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2014-08-07 WO claimed
US-8486370-B2 Heterocyclic ligands for integrin imaging and therapy THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2013-07-16 US claimed
US-20110195907-A1 AMINO ACID AND PEPTIDE CONJUGATES OF AMILORIDE AND METHODS OF USE THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA OFFICE OF TECHNOLOGY TRANSFER (US) 2011-08-11 US claimed
US-7863415-B2 Amino acid and peptide conjugates of amiloride and methods of use thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2011-01-04 US claimed
US-20100310455-A1 Heterocyclic Ligands for Integrin Imaging and Therapy THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-12-09 US claimed
US-7576175-B2 Amino acid terminated diphenylurea derivatives; display high binding affinity, specificity, and stability; use in treating cancer, inflammatory diseases, and autoimmune diseases THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2009-08-18 US claimed
US-20060160746-A1 Amino acid and peptide conjugates of amiloride and methods of use thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2006-07-20 US claimed
WO-2005073247-A1 AMINO ACID AND PEPTIDE CONJUGATES OF AMILORIDE AND METHODS OF USE THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2005-08-11 WO claimed
US-20260116855-A1 ORALLY ACTIVE MELANOCORTIN RECEPTOR-4 COMPOUNDS PALATIN TECHNOLOGIES INC (US) 2026-04-30 US disclosed
US-12612605-B2 Carboxyesterase polypeptides for kinetic resolution CODEXIS, INC. (US) 2026-04-28 US disclosed
US-20260083852-A1 PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR UNIV CALIFORNIA (US) 2026-03-26 US disclosed
EP-0859785-A1 CYCLIC PEPTIDE ANALOGS OF SOMATOSTATIN BIOMEASURE, INC. (US) 1998-08-26 EP disclosed
US-5708135-A INHIBIT INSULIN RELEASE, TREATMENT OF DIABETES, MEDICAL IMAGING WITH IODINATED DERIVATIVES BIOMEASURE INCORPORATED (US) 1998-01-13 US disclosed
WO-1997011962-A1 CYCLIC PEPTIDE ANALOGS OF SOMATOSTATIN BIOMEASURE, INCORPORATED (US) 1997-04-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100310455-A1 Heterocyclic Ligands for Integrin Imaging and Therapy ITGA1, ITGAL, ITGA4 HDAC8 1295/4885HDAC3 634/4885HDAC1 755/4885
US-20110195907-A1 AMINO ACID AND PEPTIDE CONJUGATES OF AMILORIDE AND METHODS OF USE THEREOF VIP, SLC1A1, SLC1A3 HDAC8 3874/4885HDAC3 3914/4885HDAC1 3239/4885
US-12612605-B2 Carboxyesterase polypeptides for kinetic resolution CES1, CPA1, RNGTT HDAC8 2821/4885HDAC3 4548/4885HDAC1 4800/4885
US-20260083852-A1 PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR PDGFA, DCLRE1A, PDGFRA HDAC8 4499/4885HDAC3 3823/4885HDAC1 4204/4885
US-20060160746-A1 Amino acid and peptide conjugates of amiloride and methods of use thereof VIP, SLC1A1, SLC1A3 HDAC8 3874/4885HDAC3 3914/4885HDAC1 3239/4885
US-20260116855-A1 ORALLY ACTIVE MELANOCORTIN RECEPTOR-4 COMPOUNDS MC1R, MC3R, MC5R HDAC8 532/4885HDAC3 426/4885HDAC1 821/4885
US-20150368480-A1 ANTIFOULING MATERIALS PFAS, FLNB, FLNA HDAC8 4472/4885HDAC3 1422/4885HDAC1 3146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.